A Phase 2 interventional study of Nilotinib in Chronic Myelogenous Leukemia - Chronic Phase, sponsored by Novartis Pharmaceuticals. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 51st largest by enrollment, is one of 5 that started in 2008, is one of 25 in phase 2, and was the 9th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 52nd largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2008, is one of 19 in phase 2, and was the 26th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
This study's enrollment of 18 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid, Chronic-Phase. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Select Inclusion Criteria:
A suboptimal molecular response to imatinib defined as:
Select Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nilotinib
Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
Also known as: Tasigna, AMN 107
Log Change From Baseline in Breakpoint Cluster Region Gene (BCR) - Abelson Proto-oncogene (ABL) (Bcr-Abl) Transcript Levels
The change on a logarithmic scale at 12 months from a standardized baseline value (100% on the international scale \[IS\]) in Bcr-Abl transcripts as assessed by peripheral blood Quantitative real-time polymerase chain reaction (RQ-PCR).
Time frame: From Baseline up to 12 Months
Number of Participants Who Achieved Major Molecular Response (MMR)
Major Molecular Response (MMR) value at molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized InteYesrferon versus STI571 (IRIS) study or 0.1 percent (%) per International Scale (IS).
Time frame: From Baseline up to 12 Months
Number of Participants Achieved Reduction From a Standardized Baseline Value in Bcr-Abl Transcript Levels up to Month 12
Number of participants experiencing either a greater than or equal to (\>or=) 1, \>or= 2, or \>or= 3 log10 reduction in Bcr-Abl transcript levels from Baseline to End of Cycle (EOC) 45 (Day1219 - Day1302) were presented.
Time frame: From Baseline up to 12 Months
Median Time to Best Molecular Response
The median time to best molecular response, defined as the time (in months) from the date of enrollment to the date when the maximum reduction in Bcr-Abl transcript level was observed.
Time frame: From Start of Study up to End of the Study (up to 41 Months)
Duration of Best Molecular Response
Duration of best molecular response, defined as the time (in months) from the date of best molecular response to a date when an increase in \>1 log10 was observed
Time frame: From Start of Study up to End of the Study (up to 41 Months)
Number of Participants With an Event-free Survival
Event-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of any of the following: loss of complete hematological response (CHR), loss of Complete cytogenetic response (CCyR), \>1 log increase in Bcr-Abl transcripts from the lowest recorded value, progression to accelerated or blast phase, and death.
Time frame: From Start of Study up to End of the Study (up to 41 Months)
Number of Participants With a Progression-free Survival
Progression-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of progression to Accelerated phase (AP) or Blast crisis (BC) phase, chronic myelogenous leukemia (CML) or death. Participants who did not have an event or dropped out without an event are considered censored at the date of the last observed event.
Time frame: From Start of Study up to End of the Study (up to 41 Months)
Number of Participants With an Overall Survival
Overall survival was defined as the number of participants from enrollment to the date of death.
Time frame: From Start of Study Enrollment up to End of the Study (up to 41 Months)
The study was conducted at 12 centers in United States.
| Milestone | Nilotinib |
|---|---|
| Started | 18 |
| Completed | 0 |
| Not completed | 18 |
| Withdrew: Adverse event | 2 |
| Withdrew: Abnormal laboratory value | 3 |
| Withdrew: Protocol deviation | 2 |
| Withdrew: Treatment duration completed as per protocol | 11 |
The change on a logarithmic scale at 12 months from a standardized baseline value (100% on the international scale \[IS\]) in Bcr-Abl transcripts as assessed by peripheral blood Quantitative real-time polymerase chain reaction (RQ-PCR).
| log change | Nilotinib |
|---|---|
| Baseline | 2.229 ± 0.6165 |
| Month 12 | 3.612 ± 0.5689 |
Major Molecular Response (MMR) value at molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized InteYesrferon versus STI571 (IRIS) study or 0.1 percent (%) per International Scale (IS).
| Participants | Nilotinib |
|---|---|
| Baseline — Response: Yes | 0 |
| Baseline — Response: No | 18 |
| Baseline — Response: Missing | 0 |
| Month 12 — Response: Yes | 9 |
| Month 12 — Response: No | 3 |
| Month 12 — Response: Missing | 6 |
Number of participants experiencing either a greater than or equal to (\>or=) 1, \>or= 2, or \>or= 3 log10 reduction in Bcr-Abl transcript levels from Baseline to End of Cycle (EOC) 45 (Day1219 - Day1302) were presented.
| Participants | Nilotinib |
|---|---|
| >or=1 log10 reduction | 12 |
| >or= 2 log10 reduction | 12 |
| >or= 3 log10 | 9 |
The median time to best molecular response, defined as the time (in months) from the date of enrollment to the date when the maximum reduction in Bcr-Abl transcript level was observed.
| months | Nilotinib |
|---|---|
| Median Time to Best Molecular Response | 13.8 (4.2 to 23.1) |
Duration of best molecular response, defined as the time (in months) from the date of best molecular response to a date when an increase in \>1 log10 was observed
No measurements were reported for this outcome.
Event-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of any of the following: loss of complete hematological response (CHR), loss of Complete cytogenetic response (CCyR), \>1 log increase in Bcr-Abl transcripts from the lowest recorded value, progression to accelerated or blast phase, and death.
| Participants | Nilotinib |
|---|---|
| Event | 1 |
| Censor | 17 |
Progression-free survival was defined as the number of participants from the date of enrollment to the date of first occurrence of progression to Accelerated phase (AP) or Blast crisis (BC) phase, chronic myelogenous leukemia (CML) or death. Participants who did not have an event or dropped out without an event are considered censored at the date of the last observed event.
| Participants | Nilotinib |
|---|---|
| Censor | 15 |
| Missing | 3 |
Overall survival was defined as the number of participants from enrollment to the date of death.
| Participants | Nilotinib |
|---|---|
| Number of Participants With an Overall Survival | 18 |
Collected over From Start of Study to End of the Study (up to 41 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | 0/18 (0%) | 3/18 (16.7%) | 18/18 (100%) |
| Event | Nilotinib |
|---|---|
| BradycardiaCardiac disorders | 1/18 |
| VertigoEar and labyrinth disorders | 1/18 |
| PancreatitisGastrointestinal disorders | 1/18 |
| PneumoniaInfections and infestations | 1/18 |
| SinusitisInfections and infestations | 1/18 |
| Event | Nilotinib |
|---|---|
| FatigueGeneral disorders | 6/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/18 |
| HeadacheNervous system disorders | 5/18 |
| RashSkin and subcutaneous tissue disorders | 5/18 |
| NauseaGastrointestinal disorders | 4/18 |
| SinusitisInfections and infestations | 4/18 |
| Upper respiratory tract infectionInfections and infestations | 4/18 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/18 |
| Dry eyeEye disorders | 3/18 |
The analysis was performed in Intent-to-treat (ITT) population, defined as all enrolled participants who received at least 1 dose of study drug and had at least 1 post-baseline assessment.
| Age, Continuous(years) | Nilotinib |
|---|---|
| Mean | 45.7 ± 12.15 |
| Sex: Female, Male(Participants) | Nilotinib |
|---|---|
| Female | 7 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | Nilotinib |
|---|---|
| Caucasian | 14 |
| Black | 0 |
| Asian | 1 |
| Other | 3 |
The record gives a start of Oct 2008, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2021, 9 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →